{"entity":{"id":"atara-biotherapeutics","kind":"company","name":"Atara Biotherapeutics","aka":["Atara Biotherapeutics, Inc.","NASDAQ:ATRA"],"tldr":"Atara Biotherapeutics is the Californian company behind Ebvallo, the first approved off-the-shelf T-cell therapy, which treats Epstein-Barr virus lymphoma after transplant using T cells from healthy donors.","summary":"Atara Biotherapeutics develops allogeneic Epstein-Barr virus-specific T-cell therapies. Tabelecleucel (Ebvallo), made from banked donor T cells matched by HLA, was approved in the European Union in December 2022 and by the FDA in 2025 for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease; Pierre Fabre holds worldwide commercial rights. Atara's EBV-targeted CAR-T programme ATA3219 for lymphoma and lupus was paused in 2025 as the company restructured.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.atarabio.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["tabelecleucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Thousand Oaks, California","country":"US","companyType":"cell-therapy","website":"https://www.atarabio.com/","ticker":"NASDAQ:ATRA","founded":2012,"stage":"public","investors":[],"funding":[]},"route":"/companies/atara-biotherapeutics/","neighbours":{"drug":[{"id":"tabelecleucel","kind":"drug","name":"Tabelecleucel","route":"/drugs/tabelecleucel/"}]}}